Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2022-04-28 Earnings Release
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
First quarter 2022 financial report
Earnings Release Classification · 98% confidence The document explicitly states it is the "First quarter 2022 financial report" and proceeds to list key financial highlights (Sales revenue, EBITDA) and operational updates for that period. This content structure aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results, typically containing key highlights before a more comprehensive Interim Report (IR) might be filed. The document also mentions a webcast to present the results, further confirming its nature as an earnings announcement. Since it focuses on the highlights of the first quarter, 'ER' is the most appropriate classification over 'IR' (which implies a more comprehensive report). Q1 2022
2022-04-28 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is explicitly titled "GENTIAN DIAGNOSTICS ASA NOTICE OF ANNUAL GENERAL MEETING". It details the time, place, and agenda for a general meeting, including items like election of chair, approval of financial statements, remuneration reports, and election of board members. This content directly corresponds to the materials distributed for an Annual General Meeting (AGM). Although it mentions the Annual Report (Item 4), the document itself is the notice convening the meeting, which falls under the AGM-R category.
2022-04-27 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 98% confidence The document explicitly states 'NOTICE OF ANNUAL GENERAL MEETING' and provides the date, time, and location for the meeting. It also mentions that the full notice including appendices is enclosed and will be made available online. This content is directly related to the upcoming Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). Although it is a notice, the core subject matter is the AGM itself, which is covered by AGM-R, rather than just announcing the publication of a report (RPA). Given the short length and direct focus on the meeting details, AGM-R is the most specific fit.
2022-04-27 English
Invitation to presentation of first quarter 2022 results
Report Publication Announcement Classification · 98% confidence The document is an 'Invitation to presentation of first quarter 2022 results'. It announces a future event (presentation) related to the Q1 2022 financial results and provides registration details for a webcast. This is not the actual earnings release (ER) or the interim report (IR) itself, but an announcement about the presentation of those results. Since the document is very short (556 chars) and serves primarily to announce the timing and access method for a results presentation, it fits best under Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports/events, or potentially Regulatory Filings (RNS) if RPA is too specific. Given the context of announcing a results presentation, RPA is the most precise fit.
2022-04-21 English
Gentian Diagnostics signs distribution agreement with leading global diagnostics company for Cystatin C
Regulatory Filings Classification · 95% confidence The document is a press release dated April 20, 2022, announcing that Gentian Diagnostics ASA has signed a distribution agreement for its Cystatin C Immunoassay with a major global diagnostics company, covering the United States. This is a specific corporate event announcement related to commercial strategy and market expansion, not a periodic financial report (like 10-K or IR), a formal voting result, or a management change. It details a significant business development. Since there is no specific category for 'Commercial Agreement Announcement,' and it is a formal, non-financial regulatory-style announcement, the most appropriate general category is 'Regulatory Filings' (RNS), which serves as a fallback for miscellaneous corporate announcements that don't fit the highly specific financial or governance codes. Given the short length and announcement nature, it is not the full report itself.
2022-04-20 English
Gentian Diagnostics signs distribution agreement with leading global diagnostics company for Cystatin C
Regulatory Filings Classification · 95% confidence The document is a press release dated April 20, 2022, announcing that Gentian Diagnostics has signed a distribution agreement for its Cystatin C Immunoassay with a major global diagnostics company, covering the US market. It discusses commercial strategy, revenue growth related to the product, and regulatory clearance (FDA-510(k)). The text concludes with contact information and a statement that the information is considered inside information subject to disclosure requirements under EU Market Abuse Regulation and Norwegian Securities Trading Act, published as a 'stock exchange announcement'. This type of material—a specific, material business update released via a stock exchange mechanism—is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if it were about raising money, but since it's a significant commercial partnership announcement often mandated for immediate disclosure, RNS is the most appropriate general regulatory disclosure category when a more specific one like M&A (TAR) or Director's Dealing (DIRS) does not apply. Given the options, RNS serves as the best fit for a mandatory stock exchange announcement of a material event that isn't strictly financial results (ER/IR) or governance (DEF 14A/CGR).
2022-04-20 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.